Iovance Biotherapeutics

Iovance Biotherapeutics, Inc.
Formerly	Lion Biotechnologies, Inc.
Company type	Public
Traded as	Nasdaq: IOVA ; Russell 2000 component;
Industry	Biotechnology ; Pharmaceutical ; Cancer immunotherapy ;
Founded	2007;19 years ago
Headquarters	San Carlos, California, U.S.
Key people	Steven Rosenberg Interim CEO: Frederick G. Vogt
Number of employees	319 (December 31, 2021)
Website	iovance.com

Last updated April 18, 2026

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.^[2]^[3]

History

The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became Lion Bio Pharma,^[4] which was then rebranded to Iovance in 2017.^[5]

In 2024, the US FDA gave accelerated approval to Lifileucel, marketed under the brand name Amtagavi. the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma.^[6]. The company, which is currently trialing its TIL treatment for other cancers, released promising treatment response data for non-small cell lung cancer.^[7]

References

↑ https://www.iovance.com/management/
↑ Garber, Ken (7 August 2019). "Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up". Nature Biotechnology . Retrieved 14 August 2019.
↑ Adelman, Jacob (29 May 2019). "New Navy Yard lab and office complex planned for Calif. cell-therapy research firm Iovance". The Philadelphia Inquirer . Retrieved 14 August 2019.
↑ "Genesis Biopharma completes merger with Lion Biotech". www.thepharmaletter.com. Retrieved 2026-03-10.
↑ "Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies". www.businesswire.com. 2013-07-25. Retrieved 2020-01-17.
↑ Mullard, Asher (2024-02-19). "FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers" . Nature Reviews Drug Discovery. doi:10.1038/d41573-024-00035-1. PMID 38374249.
↑ https://www.curetoday.com/view/amtagvi-prompts-responses-in-non-small-cell-lung-cancer

External links

Official website
Business data for Iovance Biotherapeutics, Inc.:

This United States corporation or company article is a stub. You can help Wikipedia by adding missing information.

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by adding missing information.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] ttps://www.iovance.com/management/

[2] Garber, Ken (7 August 2019). "Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up". Nature Biotechnology . Retrieved 14 August 2019.

[3] Adelman, Jacob (29 May 2019). "New Navy Yard lab and office complex planned for Calif. cell-therapy research firm Iovance". The Philadelphia Inquirer . Retrieved 14 August 2019.

[4] "Genesis Biopharma completes merger with Lion Biotech". www.thepharmaletter.com. Retrieved 2026-03-10.

[5] "Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies". www.businesswire.com. 2013-07-25. Retrieved 2020-01-17.

[6] Mullard, Asher (2024-02-19). "FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers" . Nature Reviews Drug Discovery. doi:10.1038/d41573-024-00035-1. PMID 38374249.

[7] ttps://www.curetoday.com/view/amtagvi-prompts-responses-in-non-small-cell-lung-cancer

[1]

[2]

[3]

[4]

[5]

[6]

[7]

Iovance Biotherapeutics

Contents

History

See also

References

External links